Atlas

FDA-Inspected Site

Delta Pharma, Inc.

10 FDA inspections are on record for Delta Pharma, Inc. in Ripley, United States.

483· Form 483 issued

Ripley, United States · Last updated July 9, 2026

Overview

  • 10 FDA inspections are on record.
  • 8 inspections produced a Form 483.
  • The most recent recorded inspection date is 2025-11-21.

At a glance

Inspections

10

Form 483s

8

EIRs

0

Last outcome

Form 483

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
10 Nov 2025 – 21 Nov 2025Human Drugs483View 483 →
9 Apr 2024 – 12 Apr 2024Human Drugs483View 483 →
22 May 2023 – 2 Jun 2023Human Drugs483View 483 →
10 May 2022 – 20 May 2022Human Drugs483View 483 →
13 Feb 2017 – 23 Feb 2017Human Drugs483On file
16 May 2016 – 24 May 2016Human Drugs483On file
24 Sep 2013 – 2 Oct 2013Human Drugs483View 483 →
17 Sep 2010Not recorded483View 483 →
17 Oct 2007Not recordedClean
10 Mar 2004Not recordedClean

Observations on record

Form 483 observations cited at this site, most recent first.

21 Nov 2025
21 CFR 211.87

Retest of approved components/containers/closures

Cited by Jared P Stevens, Lareese K Thomas

21 Nov 2025
FDCA 503B(a)(10)(A)

Drug product labels, fails to include

Cited by Jared P Stevens, Lareese K Thomas

12 Apr 2024
21 CFR 211.110(a)

Written in-process control procedures

Cited by Margaret M Annes

12 Apr 2024
21 CFR 211.80(a)

Written Procedures Not Followed

Cited by Margaret M Annes

12 Apr 2024
21 CFR 211.84(b)

Representative Samples

Cited by Margaret M Annes

Investigators

FDA investigators tied to this site in the record.

Lareese K Thomas2 insp.
Brandon C Heitmeier2 insp.
Marvin D Jones2 insp.
Zada L Giles2 insp.
Jared P Stevens1 insp.
Margaret M Annes1 insp.
Sonya M Edmonds1 insp.
Jennifer Lalama1 insp.
Regan T Harp1 insp.
Diane P Goyette1 insp.
Shelby N Marler1 insp.
Wayne S Fortenberry1 insp.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations3x
21 CFR 211.68(a)Cited across public-safe Form 483 observations3x
21 CFR 211.110(a)Cited across public-safe Form 483 observations2x
21 CFR 211.113(b)Cited across public-safe Form 483 observations2x
21 CFR 211.166(a)Cited across public-safe Form 483 observations2x
21 CFR 211.28(a)Cited across public-safe Form 483 observations2x
21 CFR 211.42(c)(10)(v)Cited across public-safe Form 483 observations2x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations2x
21 CFR 211.142(b)Cited across public-safe Form 483 observations1x
21 CFR 211.165(a)Cited across public-safe Form 483 observations1x
21 CFR 211.188Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iii)Cited across public-safe Form 483 observations1x
21 CFR 211.58Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x
21 CFR 211.80(a)Cited across public-safe Form 483 observations1x
21 CFR 211.80(b)Cited across public-safe Form 483 observations1x
21 CFR 211.84(b)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(6)Cited across public-safe Form 483 observations1x
21 CFR 211.87Cited across public-safe Form 483 observations1x
FDCA 503B(a)(10)(A)Cited across public-safe Form 483 observations1x

Full site report

Get the verbatim findings behind Delta Pharma, Inc.'s 8 Form 483s

Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat